ABSI
Absci Corporation
1W: +2.1%
1M: +7.8%
3M: -20.4%
YTD: -19.1%
1Y: -5.8%
3Y: +83.7%
$2.92
-0.09 (-2.99%)
After Hours: $2.86 (-0.06, -2.05%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$8.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$439.1M
52W Range2.01-5.228
Volume7,130,520
Avg Volume3,421,852
Beta2.13
Dividend—
Analyst Ratings
Company Info
CEOSean McClain
Employees156
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-22
Websiteabsci.com
18105 SE Mill Plain Boulevard
Vancouver, WA 98683
US
Vancouver, WA 98683
US
360 949 1041
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Latest News
Absci (ABSI) Q4 2025 Earnings Call Transcript
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket
Absci outlines $25B annual market potential for ABS-201 in AGA and advances endometriosis clinical program
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Busch Andreas | P-Purchase | 100,000 | $2.29 | 2026-03-12 |
| McClain Sean | F-InKind | 25,316 | $2.80 | 2026-03-03 |
| Bedrick Todd | F-InKind | 5,282 | $2.80 | 2026-03-03 |
| Jonasson Zachariah | F-InKind | 10,848 | $2.80 | 2026-03-03 |
| Busch Andreas | F-InKind | 1,257 | $2.80 | 2026-03-03 |